Given the central role of NF-κB in cancer progression and therapy resistance, the ability of WFA to suppress NF-κB activity could represent a critical mechanism by which it potentiates the efficacy of GC in treating pancreatic cancer. The gene discussed is NFKB1; the disease is pancreatic neoplasm.